Ganciclovir

Generic Name: Ganciclovir

Brand Names: Cytovene, Zirgan

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₅O_₄

CAS Number: 82410-32-0

Unique Ingredient Identifier: P9G3CKZ4P5

Background: An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

Indication: For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.

Associated Conditions: CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Phase 3

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 180

Registration Number: NCT00000688

Locations: 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸
Stanford Univ School of Medicine, Stanford, California, United States
🇺🇸
Kansas City Veterans Administration Med Ctr, Kansas City, Missouri, United States

and more 19 locations

CMV Retinitis Retreatment Trial

Phase 2

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00000766

Locations: 🇺🇸
Johns Hopkins Hosp / SOCA, Baltimore, Maryland, United States
🇺🇸
New York Hosp - Cornell Med Ctr / Sloan - Kettering / SOCA, New York, New York, United States
🇺🇸
Mount Sinai Med Ctr / SOCA, New York, New York, United States

and more 6 locations

Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis

Phase 4

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-02-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00000894

Locations: 🇺🇸
Cornell Univ Med Ctr, New York, New York, United States
🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸
New York Hosp / Cornell Med Ctr, New York, New York, United States

and more 9 locations

A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.

Phase 3

Completed

Conditions: Cytomegalovirus Infections

First Posted Date: 2001-08-31

Last Posted Date: 2010-08-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 130

Registration Number: NCT00001100

Locations: 🇺🇸
NIAID/DMID/CASG Central Unit, Birmingham, Alabama, United States

A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis

Phase 3

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-09-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00000698

Locations: 🇺🇸
Natl Inst of Allergy & Infect Dis / Cln Ctr, Bethesda, Maryland, United States

Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR

Not Applicable

Conditions: Cytomegalovirus Infections

First Posted Date: 2000-02-21

Last Posted Date: 2005-06-24

Lead Sponsor: National Center for Research Resources (NCRR)

Registration Number: NCT00004573

Locations: 🇺🇸
Infectious Diseases Division, St. Louis, Missouri, United States

Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection

Phase 3

Completed

Conditions: Cytomegalovirus Infections

First Posted Date: 1999-10-19

Last Posted Date: 2005-06-24

Lead Sponsor: National Center for Research Resources (NCRR)

Target Recruit Count: 130

Registration Number: NCT00004278

Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)

Phase 3

Completed

Conditions: HIV Infections
Acquired Immunodeficiency Syndrome
Cytomegalovirus Retinitis

Interventions: Drug: Ganciclovir
Drug: Foscarnet

First Posted Date: 1999-09-24

Last Posted Date: 2015-09-14

Lead Sponsor: Johns Hopkins Bloomberg School of Public Health

Target Recruit Count: 279

Registration Number: NCT00000134

Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)

Phase 3

Completed

Conditions: HIV Infections
Cytomegalovirus Retinitis

Interventions: Drug: Foscarnet
Drug: Ganciclovir

First Posted Date: 1999-09-24

Last Posted Date: 2015-10-22

Lead Sponsor: Johns Hopkins Bloomberg School of Public Health

Target Recruit Count: 234

Registration Number: NCT00000136

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy